HSBC Holdings’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$84.6M Sell
463,652
-40,180
-8% -$7.4M 0.04% 378
2025
Q4
$88.8M Buy
503,832
+56,314
+13% +$9.2M 0.05% 349
2025
Q3
$62.6M Buy
447,518
+4,249
+1% +$574K 0.03% 434
2025
Q2
$55.6M Sell
443,269
-40,760
-8% -$5.08M 0.03% 459
2025
Q1
$66M Buy
484,029
+43,028
+10% +$6.15M 0.04% 404
2024
Q4
$67.2M Buy
441,001
+26,605
+6% +$4.49M 0.04% 413
2024
Q3
$80.3M Buy
414,396
+35,959
+10% +$7.52M 0.05% 371
2024
Q2
$87.7M Sell
378,437
-20,405
-5% -$4.43M 0.05% 313
2024
Q1
$86M Buy
398,842
+73,234
+22% +$17.2M 0.06% 316
2023
Q4
$84.2M Buy
325,608
+52,974
+19% +$13M 0.07% 279
2023
Q3
$70.1M Sell
272,634
-10,875
-4% -$2.91M 0.07% 286
2023
Q2
$80.7M Buy
283,509
+33,429
+13% +$9.95M 0.08% 239
2023
Q1
$69.5M Sell
250,080
-31,858
-11% -$8.82M 0.08% 244
2022
Q4
$77.6M Buy
281,938
+111,755
+66% +$31.6M 0.09% 232
2022
Q3
$45.4M Sell
170,183
-36,149
-18% -$7.68M 0.07% 267
2022
Q2
$42.4M Buy
206,332
+40,071
+24% +$8.19M 0.06% 331
2022
Q1
$35.1M Buy
166,261
+10,034
+6% +$2.18M 0.04% 420
2021
Q4
$37.6M Buy
156,227
+400
+0.3% +$103K 0.03% 477
2021
Q3
$44.3M Sell
155,827
-18,240
-10% -$5.98M 0.04% 368
2021
Q2
$60.2M Sell
174,067
-88,967
-34% -$27M 0.06% 286
2021
Q1
$73.2M Sell
263,034
-6,908
-3% -$1.86M 0.09% 225
2020
Q4
$65.8M Buy
269,942
+38,382
+17% +$9.9M 0.09% 211
2020
Q3
$65.7M Sell
231,560
-39,559
-15% -$11M 0.1% 167
2020
Q2
$72.5M Buy
271,119
+77,992
+40% +$23.4M 0.14% 129
2020
Q1
$61M Sell
193,127
-150,229
-44% -$45.6M 0.14% 136
2019
Q4
$101M Buy
343,356
+78,036
+29% +$21.7M 0.18% 107
2019
Q3
$61.8M Sell
265,320
-2,044
-0.8% -$476K 0.12% 175
2019
Q2
$62.5M Sell
267,364
-44,384
-14% -$10.2M 0.12% 159
2019
Q1
$73.7M Buy
311,748
+91,994
+42% +$29M 0.13% 152
2018
Q4
$66.1M Sell
219,754
-3,856
-2% -$1.23M 0.12% 165
2018
Q3
$79M Buy
223,610
+26,419
+13% +$9.1M 0.13% 155
2018
Q2
$57.2M Sell
197,191
-166,909
-46% -$46.9M 0.1% 165
2018
Q1
$99.7M Buy
364,100
+35,143
+11% +$10.9M 0.15% 120
2017
Q4
$105M Sell
328,957
-16,783
-5% -$5.38M 0.15% 128
2017
Q3
$108M Buy
345,740
+42,816
+14% +$12.7M 0.17% 107
2017
Q2
$82.2M Buy
302,924
+20,912
+7% +$5.53M 0.15% 122
2017
Q1
$77M Buy
282,012
+92,123
+49% +$26M 0.16% 112
2016
Q4
$53.8M Buy
189,889
+14,462
+8% +$4.29M 0.13% 173
2016
Q3
$54.7M Buy
175,427
+3,668
+2% +$1.09M 0.14% 148
2016
Q2
$41.5M Sell
171,759
-49
-0% -$12.9K 0.11% 200
2016
Q1
$44.5M Sell
171,808
-64,169
-27% -$17M 0.13% 188
2015
Q4
$72.4M Sell
235,977
-127,376
-35% -$36.6M 0.17% 117
2015
Q3
$106M Sell
363,353
-6,606
-2% -$2.18M 0.27% 81
2015
Q2
$149M Sell
369,959
-23,695
-6% -$9.51M 0.3% 69
2015
Q1
$166M Buy
393,654
+26,769
+7% +$10.6M 0.32% 63
2014
Q4
$125M Buy
366,885
+49,843
+16% +$16.1M 0.26% 79
2014
Q3
$105M Sell
317,042
-33,404
-10% -$11M 0.22% 95
2014
Q2
$111M Buy
350,446
+17,700
+5% +$5.33M 0.24% 94
2014
Q1
$101M Buy
332,746
+31,897
+11% +$10.1M 0.24% 90
2013
Q4
$84.1M Buy
300,849
+22,756
+8% +$5.89M 0.22% 93
2013
Q3
$67.1M Buy
278,093
+7,623
+3% +$1.71M 0.18% 121
2013
Q2
$58M Buy
+270,470
New +$57.8M 0.17% 118

Other funds holding BIIB

HSBC Holdings's BIIB Position: Q1 2026 in Review

HSBC Holdings reduced its Biogen (BIIB) stake by 8% in Q1 2026, selling an estimated $7.4M and leaving 463,652 shares worth $84.6M. The position accounts for 0.04% of the portfolio, ranked #378.

HSBC Holdings first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • HSBC Holdings held 463,652 shares of Biogen worth $84.6M as of Q1 2026.
  • HSBC Holdings sold 40,180 Biogen shares in Q1 2026, an estimated $7.4M.
  • Biogen made up 0.04% of HSBC Holdings's portfolio in Q1 2026, its #378 holding.
  • HSBC Holdings first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
  • HSBC Holdings's Biogen position peaked at $166M in Q1 2015.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.